Hyung Lae Kim

Hyung Lae Kim

Auto-generated profile, based on publicly available information

Hyung Lae Kim

Department of Urology, Cedars-Sinai Medical Center, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2010 in BJU International
Verified
Journal Article
Closed access
PDF file
MHMatthew H. Hayn
Matthew H. Hayn
TSThomas Schwaab
Thomas Schwaab
WUWillie Underwood
Willie Underwood
HKHyung L. Kim
Hyung L. Kim

1 August 2015 in Urology
Verified
Journal Article
Closed access
TFTom S. Feng
Tom S. Feng
ASAli Reza Sharif-Afshar
Ali Reza Sharif-Afshar
JWJonathan Wu
Jonathan Wu
QLQuanlin Li
Quanlin Li
DLDaniel Luthringer
Daniel Luthringer
HKHyung L. Kim
Hyung L. Kim

1 September 2010 in Journal of Urology
Verified
Journal Article
Closed access
NHNicholas J. Hellenthal
Nicholas J. Hellenthal
WUWillie Underwood
Willie Underwood
RPRemedios Penetrante
Remedios Penetrante
ALAlan Litwin
Alan Litwin
SZShaozeng Zhang
Shaozeng Zhang
HKHyung L. Kim
Hyung L. Kim
Sunitinib is an approved treatment for metastatic renal cell carcinoma. We performed a prospective clinical trial to evaluate the safety and clinical response to sunitinib administered before nephrectomy in patients with localized or metastatic clear cell renal cell carcinoma. Patients with biopsy proven clear cell renal cell carcinoma were enrolled in the study and treated with 37.5 mg sunitinib malate daily for 3 months before nephrectomy. The primary end point was safety. In an 18-month period 20 patients were enrolled. The most common toxicities were gastrointestinal symptoms and hematological effects. Grade 3 toxicity developed in 6 patients (30%). No surgical complications were attributable to sunitinib treatment. Of the 20 patients 17 (85%) experienced reduced tumor diameter (mean change -11.8%, range -27% to 11%) and cross-sectional area (mean change -27.9%, range -43% to 23%). Enhancement on contrast enhanced computerized tomography decreased in 15 patients (mean HU change -22%, range -74% to 29%). After tumor reduction 8 patients with cT1b disease underwent laparoscopic partial nephrectomy. Surgical parameters, such as blood loss, transfusion rate, operative time and complications, were similar to those in patients who underwent surgery during the study period and were not enrolled in the trial. Preoperative treatment with sunitinib is safe. Sunitinib decreased the size of primary renal cell carcinoma in 17 of 20 patients. Future trials can be considered to evaluate neoadjuvant sunitinib to maximize nephron sparing and decrease the recurrence of high risk, localized renal cell carcinoma.

1 February 2011 in British Journal of Cancer
Verified
Journal Article
Open access
YWY Wang
Y Wang
XWX-Y Wang
X-Y Wang
JSJ R Subjeck
J R Subjeck
PSP A Shrikant
P A Shrikant
HKH L Kim
H L Kim
Background: Methods: Results: Conclusion:

12 December 2018 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
HKHyung L. Kim
Hyung L. Kim
PLPing Li
Ping Li
HHHuei-Chung Huang
Huei-Chung Huang
SDSamineh Deheshi
Samineh Deheshi
TMTara Marti
Tara Marti
Tarek BismarTarek Bismar
Tarek Bismar
Background Many men diagnosed with prostate cancer are active surveillance (AS) candidates. However, AS may be associated with increased risk of disease progression and metastasis due to delayed therapy. Genomic classifiers, e.g., Decipher, may allow better risk-stratify newly diagnosed prostate cancers for AS. Methods Decipher was initially assessed in a prospective cohort of prostatectomies to explore the correlation with clinically meaningful biologic characteristics and then assessed in diagnostic biopsies from a retrospective multicenter cohort of 266 men with National Comprehensive Cancer Network (NCCN) very low/low and favorable-intermediate risk prostate cancer. Decipher and Cancer of the Prostate Risk Assessment (CAPRA) were compared as predictors of adverse pathology (AP) for which there is universal agreement that patients with long life-expectancy are not suitable candidates for AS (primary pattern 4 or 5, advanced local stage [pT3b or greater] or lymph node involvement). Results Decipher from prostatectomies was significantly associated with adverse pathologic features (p-values < 0.001). Decipher from the 266 diagnostic biopsies (64.7% NCCN-very-low/low and 35.3% favorable-intermediate) was an independent predictor of AP (odds ratio 1.29 per 10% increase, 95% confidence interval [CI] 1.03–1.61, p-value 0.025) when adjusting for CAPRA. CAPRA area under curve (AUC) was 0.57, (95% CI 0.47–0.68). Adding Decipher to CAPRA increased the AUC to 0.65 (95% CI 0.58–0.70). NPV, which determines the degree of confidence in the absence of AP for patients, was 91% (95% CI 87–94%) and 96% (95% CI 90–99%) for Decipher thresholds of 0.45 and 0.2, respectively. Using a threshold of 0.2, Decipher was a significant predictor of AP when adjusting for CAPRA (p-value 0.016). Conclusion Decipher can be applied to prostate biopsies from NCCN-very-low/low and favorable-intermediate risk patients to predict absence of adverse pathologic features. These patients are predicted to be good candidates for active surveillance.

11 December 2014 in BMC Genomics
Verified
Journal Article
Open access
PDF file
PLPing Li
Ping Li
ACAndrew Conley
Andrew Conley
HZHao Zhang
Hao Zhang
HKHyung L Kim
Hyung L Kim
Formalin-fixed paraffin-embedded (FFPE) tissue samples are routinely archived in the course of patient care and can be linked to clinical outcomes with long-term follow-up. However, FFPE tissues have degraded RNA which poses challenges for analyzing gene expression. Next-generation sequencing (NGS) is rapidly becoming accepted as an effective tool for measuring gene expressions for research and clinical use. However, the feasibility of NGS has not been firmly established when using FFPE tissue.